8-K: Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering

Phio Pharmaceuticals Corp. has entered into definitive agreements for a $2.5 million registered direct offering priced at-the-market under Nasdaq rules, along with a concurrent private placement of warrants.

Summary

• Phio Pharmaceuticals Corp. announced a registered direct offering of 833,335 shares of its common stock at $3.00 per share, priced at-the-market under Nasdaq rules.
• The company will also issue unregistered warrants in a concurrent private placement to purchase up to 1,666,670 shares of common stock.
• The warrants have an exercise price of $3.00 per share, are exercisable upon issuance, and expire 24 months from the issuance date.
• The offering is expected to close on or about January 15, 2025, pending customary closing conditions.
• H.C. Wainwright & Co. is the exclusive placement agent for the offering.
• The company expects gross proceeds of $2.5 million before deducting fees and expenses.
• Phio Pharmaceuticals intends to use the net proceeds for working capital and general corporate purposes.

Sentiment

Score: 5

Explanation: The announcement is neutral. While the capital raise is necessary for the company's operations, it also results in dilution for existing shareholders.

Positives

• The offering provides Phio Pharmaceuticals with $2.5 million in gross proceeds to bolster working capital.
• The warrants, if exercised, could provide additional capital to the company in the future.
• The offering is priced at-the-market, which can be seen as a positive for current shareholders as it reflects the current valuation.
• The company has flexibility in using the proceeds for general corporate purposes.

Negatives

• The offering dilutes existing shareholders' equity.
• The warrants, if exercised, could further dilute existing shareholders' equity.
• The company is relying on additional funding to continue operations.

Risks

• The closing of the offering is subject to customary closing conditions and may not occur.
• The warrants may not be exercised, and the company may not receive additional capital from them.
• The company's stock price could be negatively impacted by the offering.
• The company's use of proceeds may not be successful.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

Industry Context

Biotech companies, especially clinical-stage firms like Phio Pharmaceuticals, often rely on public and private offerings to fund research and development activities.

Comparison to Industry Standards

• Comparable companies such as Idera Pharmaceuticals and Dicerna Pharmaceuticals have also utilized registered direct offerings to raise capital.
• The terms of this offering, including the warrant coverage and exercise price, are within the typical range for similar financings in the biotech industry.
• The use of H.C. Wainwright & Co. as a placement agent is common for small-cap biotech companies.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares and warrants.
• The company's employees and partners may benefit from the increased financial stability.
• The company's customers may benefit from the continued development of its products.

Next Steps

• The offering is expected to close on or about January 15, 2025, subject to customary closing conditions.
• The company will file a prospectus supplement with the SEC.
• The company will use the net proceeds for working capital and general corporate purposes.

Key Dates